Article
Proteomic Assessment of SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and…
medRxiv · 2024 · Arba Karcini
Key facts
| Title | Proteomic Assessment of SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors |
|---|---|
| First author | Arba Karcini |
| Journal | medRxiv |
| Published | Apr 3, 2024 |
| DOI | 10.1101/2024.04.02.587656 |
| Devices mentioned | BK110039, DEN000008, K022086, K042152, K103302, K864267, K940422, K982100 |
| Product codes mentioned | CFN, DFZ, DPM, NDS, PCA, JCI, KIP, KIT, MVU, NJT, NQF, OOI |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1